Administrative Core
行政核心
基本信息
- 批准号:10369068
- 负责人:
- 金额:$ 27.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-17 至 2026-11-30
- 项目状态:未结题
- 来源:
- 关键词:AccountingAdvisory CommitteesAgreementAntibodiesAntigensB-LymphocytesBudgetsCell LineageClinical TrialsCommunicationDataData AnalysesData ProvenanceDevelopmentEnsureExpenditureExperimental DesignsFerritinFundingGoalsGrantGuidelinesHIV-1HIV-1 vaccineHumanHuman ResourcesIACUCImmune responseInfrastructureInstitutesInstitutional PolicyLeadMeasuresMonitorNational Institute of Allergy and Infectious DiseaseOccupational activity of managing financesOutcomeParticipantPhase I Clinical TrialsPoliciesPractice GuidelinesPreparationProductionProteinsProtocols documentationPublicationsRegulationReportingResearchResearch PersonnelResourcesRightsRiskSiteSupervisionTestingTimeUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiesVaccine ResearchVaccinesconflict resolutiondata managementdata sharingexpectationexperienceinterestmeetingsmembernanoparticlenext generation sequencingprogramsquality assurancesortasevaccine developmentvaccine platform
项目摘要
ABSTRACT- ADMINISTRATIVE CORE
The Administrative Core will coordinate the scientific and administrative activities of this IPCAVD Program,
ensuring that the Projects and Cores function well together. In particular, it will be responsible for managing the
program’s financial management, program management, and coordinating Projects and Cores through scientific
meetings and communications, as well as ensuring full financial and regulatory compliance. A primary activity
of the Core will be monitoring IPCAVD progress relative to milestones and measuring this progress against
available funding to ensure resources are used efficiently. As Specific Aims, the Core will provide overall
IPCAVD management, coordination and supervision of the Program (Aim 1), ensure timely financial accounting
and reporting (Aim 2), ensure compliance with all institutional, state, and federal research and cGMP guidelines
(Aim 3), develop and implement IPCAVD communication, publication, and data sharing plans (Aim 4), and
provide statistical support for all data analyses (Aim 5). The Core will coordinate an annual meeting with an
External Advisory Committee (EAC) that will review the progress of IPCAVD Projects and Cores, and with input
from the DAIDS Program Team, provide guidance for the Program’s direction. Core staff are part of a highly
experienced and integrated management team, which will enable immediate start-up and rapid progress.
This teamwork will accelerate advancement toward the Program’s goals, thus maximizing the opportunities to
positively impact HIV-1 vaccine research in humans.
摘要-行政核心
行政核心将协调该 IPCVD 计划的科学和行政活动,
确保项目和核心良好地协同运作,特别是,它将负责管理项目。
项目的财务管理、项目管理以及通过科学协调项目和核心
会议和沟通,以及确保财务和监管完全合规。
核心部门将监控 IPAVD 相对于里程碑的进展,并根据
作为具体目标,核心将提供全面的可用资金,以确保资源得到有效利用。
IPCVD 管理、协调和监督该计划(目标 1),确保及时进行财务会计
和报告(目标 2),确保遵守所有机构、州和联邦研究以及 cGMP 指南
(目标 3),制定并实施 IPCVD 沟通、出版和数据共享计划(目标 4),以及
为所有数据分析提供统计支持(目标 5)。
外部咨询委员会 (EAC) 将审查 IPCVD 项目和核心的进展情况,并提供意见
来自 DAIDS 项目团队的核心人员是高度重视的一部分,为该项目的方向提供指导。
经验丰富、综合性的管理团队,将能够立即启动并快速进步。
这种团队合作将加速实现该计划的目标,从而最大限度地增加机会
对人类 HIV-1 疫苗研究产生积极影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEVIN O SAUNDERS其他文献
KEVIN O SAUNDERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEVIN O SAUNDERS', 18)}}的其他基金
Conjugate nanoparticle platform development for HIV-1 envelope immunogens
HIV-1 包膜免疫原的共轭纳米颗粒平台开发
- 批准号:
10541860 - 财政年份:2021
- 资助金额:
$ 27.69万 - 项目类别:
Project 1. Optimization and in vivo evaluation of HIV-1 Env trimer sortase A-conjugated nanoparticles
项目1. HIV-1 Env三聚体分选酶A结合纳米粒子的优化及体内评价
- 批准号:
10369069 - 财政年份:2021
- 资助金额:
$ 27.69万 - 项目类别:
Conjugate nanoparticle platform development for HIV-1 envelope immunogens
HIV-1 包膜免疫原的共轭纳米颗粒平台开发
- 批准号:
10369067 - 财政年份:2021
- 资助金额:
$ 27.69万 - 项目类别:
Project 1. Optimization and in vivo evaluation of HIV-1 Env trimer sortase A-conjugated nanoparticles
项目1. HIV-1 Env三聚体分选酶A结合纳米粒子的优化及体内评价
- 批准号:
10541863 - 财政年份:2021
- 资助金额:
$ 27.69万 - 项目类别:
HIV-1 vaccine-elicited antibodies target envelope glycans
HIV-1 疫苗引发的抗体靶向包膜聚糖
- 批准号:
10454824 - 财政年份:2015
- 资助金额:
$ 27.69万 - 项目类别:
HIV-1 vaccine-elicited antibodies target envelope glycans
HIV-1 疫苗引发的抗体靶向包膜聚糖
- 批准号:
9089881 - 财政年份:2015
- 资助金额:
$ 27.69万 - 项目类别:
HIV-1 vaccine-elicited antibodies target envelope glycans
HIV-1 疫苗引发的抗体靶向包膜聚糖
- 批准号:
10082482 - 财政年份:2015
- 资助金额:
$ 27.69万 - 项目类别:
HIV-1 vaccine-elicited antibodies target envelope glycans
HIV-1 疫苗引发的抗体靶向包膜聚糖
- 批准号:
10674728 - 财政年份:2015
- 资助金额:
$ 27.69万 - 项目类别:
HIV-1 vaccine-elicited antibodies target envelope glycans
HIV-1 疫苗引发的抗体靶向包膜聚糖
- 批准号:
10219934 - 财政年份:2015
- 资助金额:
$ 27.69万 - 项目类别:
相似海外基金
Developing a Novel Decision Aid for Tracheostomy to Support Shared Decision- Making in the Intensive Care Unit
开发新型气管造口决策辅助工具,支持重症监护病房的共同决策
- 批准号:
10212444 - 财政年份:2021
- 资助金额:
$ 27.69万 - 项目类别:
Developing a Novel Decision Aid for Tracheostomy to Support Shared Decision- Making in the Intensive Care Unit
开发新型气管造口决策辅助工具,支持重症监护病房的共同决策
- 批准号:
10657564 - 财政年份:2021
- 资助金额:
$ 27.69万 - 项目类别:
Developing a Novel Decision Aid for Tracheostomy to Support Shared Decision- Making in the Intensive Care Unit
开发新型气管造口决策辅助工具,支持重症监护病房的共同决策
- 批准号:
10447771 - 财政年份:2021
- 资助金额:
$ 27.69万 - 项目类别: